Pardes Biosciences Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Pardes Biosciences Inc
Access all reports
Pardes Biosciences Inc. is a biopharmaceutical company that was focused on the discovery, development, and commercialization of novel oral antiviral therapeutics. The company targeted life-threatening diseases, including its efforts against COVID-19. Pardes Biosciences operated as a clinical-stage company, which indicates its products were in the clinical trial phase and not yet available on the market. As of August 31, 2023, Pardes Biosciences was acquired by MediPacific, Inc., and it became a wholly owned subsidiary of MediPacific. Following the acquisition, the shares of Pardes Biosciences ceased trading and were delisted from the Nasdaq stock exchange.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
PRDS
Country
🇺🇸 United States